IMUNON, Inc. Announces IMNN-101 Preclinical Data In SARS CoV-2 Published In Peer-Reviewed Journal Vaccine
Portfolio Pulse from Benzinga Newsdesk
IMUNON, Inc. (NASDAQ:IMNN) announced the publication of preclinical data for its DNA-based vaccine, IMNN-101, against SARS-CoV-2 in the peer-reviewed journal Vaccine. The study shows strong immunogenicity and protection, highlighting the vaccine's potential for broader protection against COVID-19 variants. IMUNON plans to file an IND application with the FDA soon and start a Phase 1/2 study in the spring.
February 22, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMUNON, Inc. (NASDAQ:IMNN) has published promising preclinical data for its DNA-based COVID-19 vaccine, IMNN-101, showing strong immunogenicity and protection. The company is preparing to file an IND application with the FDA and commence a Phase 1/2 study.
The publication of positive preclinical data in a prestigious journal and the upcoming IND filing and Phase 1/2 study commencement are significant milestones for IMUNON. These developments are likely to generate positive investor sentiment and could lead to an increase in stock price in the short term, given the high relevance and importance of vaccine research and development in the current global health context.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100